Stock market today: Nasdaq edges back from its record as chip companies and Eli Lilly slump
U.S. stock indexes edged lower Wednesday after drops for Eli Lilly and chip companies overshadowed a jump for Google’s parent ...
Eli Lilly's Zepbound and Mounjaro are no longer in shortage. Here's where their sales still fell short
Eli Lilly' s blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro posted weaker-than-expected sales for the ...
Taking A Look At Eli Lilly's Q3 2024 Revenue Miss Amid Supply Chain Challenges
LLY had $11.4 billion in revenue for the quarter (up 20% versus Q3 figures from last year), with a net income of $970 million ...
Eli Lilly’s third quarter earnings miss and forecast cut lead to sharp stock drop
Eli Lilly is dialing back its 2024 forecast after underwhelming Wall Street with third-quarter earnings and sales from two ...
Why Eli Lilly Stock Is Sinking Today
Type 2 diabetes drug Mounjaro and weight-loss drug Zepbound remained the brightest stars in Lilly's lineup. Mounjaro's sales ...
Eli Lilly Misses Quarterly Profit Estimates; Shares Tumble
(Reuters) -Eli Lilly missed Wall Street estimates for third-quarter profit on Wednesday, hurt by higher manufacturing costs ...
Knockoff weight loss drugs are having a moment. Eli Lilly isn't worried
CEO David Ricks said the sale of cheaper, off-brand versions of the company’s blockbuster weight loss drug isn’t having a ...
Mounjaro's Sales Likely To Rise 2.5x Driving Eli Lilly's Q3 Performance
The pharmaceutical giant is expected to garner $12.1 billion in sales and $1.45 in adjusted earnings per share, per the ...
Eli Lilly's rare sales miss for weight-loss drug sends shares tumbling
Eli Lilly missed Wall Street estimates for third-quarter profit on Wednesday, even as demand for its weight-loss drug soared, hurt by higher manufacturing and acquisition-related costs.
Eli Lilly's miss explanation is 'totally opaque', says Jim Cramer
Mookie Betts speaks out after fan tries to steal ball from La Dodgers star ...